Hanly, Mark
Churches, Tim
Fitzgerald, OisÃn
Caterson, Ian
MacIntyre, Chandini Raina
Jorm, Louisa
Funding for this research was provided by:
Ian Sharp, philanthropic supporter of UNSW research
Sydney Partnership for Health, Education, Research and Enterprise (SPHERE) Infectious diseases, Immunity and Inflammation (Triple-I) Clinical Academic Group
Article History
Received: 10 February 2022
Accepted: 3 August 2022
First Online: 19 August 2022
Declarations
:
: Not applicable.
: Not applicable.
: CRM has consulted for or been on advisory boards on COVID-19 vaccines for Seqirus, Janssen and Astrazeneca. No other authors have a competing interest to declare.